Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Opening Session Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Oct
29
Today In Oncology
How Medicare Advantage and Traditional Medicare Influence Palliative and Hospice Care Implementation
Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage SCLC
TALENT Neoadjuvant T-DXd in HER2-Low Early Breast Cancer
Adding a Chatbot to Cancer Predisposition Visits Improves Risk Knowledge in AYAs
Substudy Validates Perioperative Approach of Systemic Therapy With Radical Prostatectomy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo